Centro De Ingenieria Genetica Y Biotecnologia

Hector Santana Milian

Gerardo Enrique Guillen Nieto

Jorge Amador Berlanga Acosta

Luis Saturnino Herrera Martinez

Haydee Geronimo Perez

Jose Ignacio Fernandez Montequin

Ana Aguilera Barreto

Rolando Paez Meireles

Jorge Sotolongo Pena

Ingrid Rojas Constantin

Iraldo Bello Rivero

Leonardo Canan-Haden Frias

Yanelda Garcia Vega

Lorenzo Anasagasti Angulo

Pedro Lopez Saura

Calixto Valdes Perez

Neobalis Franco Perez

Larissa Chacon Corvea

The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.

Stabilized pharmaceutical formulations that contain the interferons gammas and alpha in synergistic proportions

The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.

Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention

Growing community of inventors

Cuidad de la Habana, Cuba

Hector Santana Milian